Obsessive-Compulsive Disorder (Central Nervous System) - Drugs in Development, 2021

Publisher Name :
Date: 31-Mar-2021
No. of pages: 72
Inquire Before Buying

Obsessive-Compulsive Disorder (Central Nervous System) - Drugs in Development, 2021

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obsessive-Compulsive Disorder - Drugs in Development, 2021, provides an overview of the Obsessive-Compulsive Disorder (Central Nervous System) pipeline landscape.

Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Risk factor includes family history. Treatment includes antidepressants and psychiatric medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obsessive-Compulsive Disorder - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Obsessive-Compulsive Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Obsessive-Compulsive Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Obsessive-Compulsive Disorder (Central Nervous System) - Drugs in Development, 2021

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Obsessive-Compulsive Disorder - Overview
Obsessive-Compulsive Disorder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Obsessive-Compulsive Disorder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development
Amorsa Therapeutics Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Cannabis Science Inc
Octapharma AG
Omeros Corp
Phytecs
Rugen Therapeutics R&D (Shanghai) Co Ltd
Seropeutics LLC
Sumitomo Dainippon Pharma Co Ltd
Obsessive-Compulsive Disorder - Drug Profiles
CBISOCD-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSP-1181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PECS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
psilocybin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize GRIN2B for Autism and Obsessive Compulsive Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target NMDA Receptor for Obsessive Compulsive Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
troriluzole hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Obsessive-Compulsive Disorder - Dormant Projects
Obsessive-Compulsive Disorder - Discontinued Products
Obsessive-Compulsive Disorder - Product Development Milestones
Featured News & Press Releases
Jan 04, 2021: Biohaven begins pivotal Phase 3 trial of troriluzole in obsessive-compulsive disorder
Jun 24, 2020: Biohaven announces obsessive compulsive disorder (OCD) proof of concept phase 2/3 study results and program update
Jan 30, 2020: Sumitomo Dainippon Pharma, Exscientia advance AI drug candidate
Sep 16, 2019: Omeros announces positive results from phase 1 study of its lead PDE7 inhibitor in development for addiction
Dec 21, 2017: Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder
Oct 24, 2017: Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder
Jul 13, 2017: Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Obsessive-Compulsive Disorder, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc, 2021
Obsessive-Compulsive Disorder - Pipeline by Biogen Inc, 2021
Obsessive-Compulsive Disorder - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2021
Obsessive-Compulsive Disorder - Pipeline by Cannabis Science Inc, 2021
Obsessive-Compulsive Disorder - Pipeline by Octapharma AG, 2021
Obsessive-Compulsive Disorder - Pipeline by Omeros Corp, 2021
Obsessive-Compulsive Disorder - Pipeline by Phytecs, 2021
Obsessive-Compulsive Disorder - Pipeline by Rugen Therapeutics R&D (Shanghai) Co Ltd, 2021
Obsessive-Compulsive Disorder - Pipeline by Seropeutics LLC, 2021
Obsessive-Compulsive Disorder - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2021
Obsessive-Compulsive Disorder - Dormant Projects, 2021
Obsessive-Compulsive Disorder - Discontinued Products, 2021

List of Figures
Number of Products under Development for Obsessive-Compulsive Disorder, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
  • Spinal cord injury - Pipeline Insight, 2021
    Published: 02-Sep-2021        Price: US 2000 Onwards        Pages: 80
    DelveInsight's, "Spinal Cord Injury - Pipeline Insight, 2021," report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Spinal Cord Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered - Globa......
  • Huntington Disease - Global Clinical Trials Review, H2, 2021
    Published: 26-Aug-2021        Price: US 2500 Onwards        Pages: 148
    Huntington Disease - Global Clinical Trials Review, H2, 2021 Summary GlobalData's clinical trial report, "Huntington Disease - Global Clinical Trials Review, H2, 2021" provides an overview of Huntington Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Huntington Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage o......
  • Epilepsy - Global Clinical Trials Review, H2, 2021
    Published: 25-Aug-2021        Price: US 2500 Onwards        Pages: 1489
    Epilepsy - Global Clinical Trials Review, H2, 2021 Summary GlobalData's clinical trial report, "Epilepsy - Global Clinical Trials Review, H2, 2021" provides an overview of Epilepsy Clinical trials scenario. This report provides top line data relating to the clinical trials on Epilepsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, cou......
  • Multiple Sclerosis - Global Clinical Trials Review, H2, 2021
    Published: 25-Aug-2021        Price: US 2500 Onwards        Pages: 1375
    Multiple Sclerosis - Global Clinical Trials Review, H2, 2021 Summary GlobalData's clinical trial report, "Multiple Sclerosis - Global Clinical Trials Review, H2, 2021" provides an overview of Multiple Sclerosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage o......
  • Global and China Central Nervous System Disorders Therapeutics Market Size, Status and Forecast 2021-2027
    Published: 25-Aug-2021        Price: US 3900 Onwards        Pages: 100
    Global Central Nervous System Disorders Therapeutics Scope and Market Size Central Nervous System Disorders Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Central Nervous System Disorders Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of rev......
  • Global CNS Therapeutics Market Development Strategy Pre and Post COVID-19, by Corporate Strategy Analysis, Landscape, Type, Application, and Leading 20 Countries
    Published: 15-Jul-2021        Price: US 4000 Onwards        Pages: 99
    Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
  • Migraine - Epidemiology Forecast to 2030
    Published: 15-Jul-2021        Price: US 3995 Onwards        Pages: 38
    Migraine - Epidemiology Forecast to 2030 Summary Migraine is a common neurological disorder characterized by intense, debilitating headaches. It is characterized by a unilateral, pulsating, or throbbing pain that is moderate to severe and is aggravated by physical activity. According to the International Classification of Headache Disorders, Third Edition (ICHD-3) criteria, migraine is considered to be one of two types based on the presence of characteristic transient f......
  • Global Central Nervous System Disorders Therapeutics Market Size, Status and Forecast 2021-2027
    Published: 14-Jul-2021        Price: US 3900 Onwards        Pages: 95
    Central Nervous System (CNS) disorders are also called as neurological and psychiatric disorders. CNS disorders can affect either the brain or spinal cord, or both. Depression is the dominated market of CNS Disorders Therapeutics Market Analysis and Insights: Global Central Nervous System Disorders Therapeutics Market The global Central Nervous System Disorders Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CA......
  • Global CNS Therapeutics Market Size, Status and Forecast 2021-2027
    Published: 12-Jul-2021        Price: US 3900 Onwards        Pages: 123
    Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs